Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny

Blood (2024) 144 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2024-210550

Published: 2024

Journal Articles

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

Blood (2024) 144 (Supplement 1): 218.

https://doi.org/10.1182/blood-2024-201058

Published: 2024

Journal Articles

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Michael Daunov, John Sumodi, Nikki Agarwal, Molly Megan Gallogly, Leland Metheny, Ben K. Tomlinson, Rebecca B. Klisovic, Ali W. Bseiso, Brett Glotzbecker, Kord Honda, Koen van Besien

Blood (2024) 144 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2024-212304

Published: 2024

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma

Melissa Copley, Leland Metheny, Rebecca B. Klisovic, Ehsan Malek

Blood (2022) 140 (Supplement 1): 13202–13203.

https://doi.org/10.1182/blood-2022-162665

Published: 2022

Journal Articles

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Elias J. Jabbour, Hagop Kantarjian, Ghayas C. Issa, Joseph Thaddeus Beck, Rebecca B. Klisovic, Sudipto Mukherjee, Vivian G. Oehler, Zi Chen, Ming Lu, Tommy Fu, Lixin Jiang, Yifan Zhai, Dajun Yang

Blood (2021) 138 (Supplement 1): 2551.

https://doi.org/10.1182/blood-2021-152693

Published: 2021

Journal Articles

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-142110

Published: 2020

Journal Articles

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Blood (2020) 135 (5): 371–380.

https://doi.org/10.1182/blood.2019002697

Published: 2020

Includes: Supplemental data

Journal Articles

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, Rebecca B. Klisovic, MD, Wendy Stock, MD, David Ungar, MD, Amer M. Zeidan, MD, Ehab Atallah, MD, James McCloskey, MD, Leonard Heffner, MD, Benjamin Tomlinson, MD, Hagop M. Kantarjian, MD, Shui He, PhD, Joseph Boni, PhD, Matthew J. Wieduwilt

Blood (2017) 130 (Supplement 1): 1321.

https://doi.org/10.1182/blood.V130.Suppl_1.1321.1321

Published: 2017

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Blood (2017) 130 (Supplement 1): 4483.

https://doi.org/10.1182/blood.V130.Suppl_1.4483.4483

Published: 2017

Journal Articles

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Blood (2017) 130 (Supplement 1): 467.

https://doi.org/10.1182/blood.V130.Suppl_1.467.467

Published: 2017

Journal Articles

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Blood (2017) 130 (Supplement 1): 2580.

https://doi.org/10.1182/blood.V130.Suppl_1.2580.2580

Published: 2017

Journal Articles

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

Ellen K Ritchie, MD, Rosalind Catchatourian, MD, Rebecca B. Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, MD, Michael R. Savona, MD, Ilva Dautaj, MS, Das Purkayastha, Karen Habucky, PhD, Michael J. Mauro, MD

Blood (2017) 130 (Supplement 1): 2875.

https://doi.org/10.1182/blood.V130.Suppl_1.2875.2875

Published: 2017

Journal Articles

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Blood (2017) 130 (Supplement 1): 145.

https://doi.org/10.1182/blood.V130.Suppl_1.145.145

Published: 2017

Journal Articles

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

Nicole R. Grieselhuber, MD PhD, Shaneice R. Mitchell, BS, Shelley Orwick, BS, Bonnie K. Harrington, DVM, Virginia M. Goettl, DVM, PhD, Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Sumithra Vasu, MBBS, William Blum, MD, James S. Blachly, MD, David M. Lucas, PhD, Ramiro Garzon, MD, Rosa Lapalombella, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3941.

https://doi.org/10.1182/blood.V128.22.3941.3941

Published: 2016

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

Alison R. Walker, MD MPH, Bhavana Bhatnagar, DO, A. Mario Q. Marcondes, MD, Julie DiPaolo, PhD, Sumithra Vasu, MBBS, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Katherine J. Walsh, MD, Renee Canning, RN, Gregory K. Behbehani, MD PhD, Ramiro Garzon, MD, James S. Blachly, MD, Amy J. Johnson, PhD, Esteban Abella-Dominicis, John C. Byrd, MD, William Blum, MD

Blood (2016) 128 (22): 2831.

https://doi.org/10.1182/blood.V128.22.2831.2831

Published: 2016

Journal Articles

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib

Ellen K. Ritchie, MD, Rose Catchatourian, MD, Rebecca B Klisovic, MD, Javier Pinilla-Ibarz, MD PhD, Michael W. Deininger, MD PhD, Harry P. Erba, MD PhD, Jerald P. Radich, Michael R. Savona, MD, Ilva Dautaj, MS, Johannes Wolff, MD, Michael J. Mauro, MD

Blood (2016) 128 (22): 3090.

https://doi.org/10.1182/blood.V128.22.3090.3090

Published: 2016

Journal Articles

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Daniel R Richardson, MD, Qiuhong Zhao, MS, Rhonda Kitzler, MS, Patrick Elder, MS, Gerard Lozanski, MD, Leslie A. Andritsos, MD, Don M Benson, MD PhD, William Blum, MD, Yvonne A Efebera, MD MPH, Samantha Jaglowski, MD MPH, Rebecca B Klisovic, MD, Sam Penza, MD, Sumithra Vasu, MBBS, Steven M Devine, MD

Blood (2016) 128 (22): 4598.

https://doi.org/10.1182/blood.V128.22.4598.4598

Published: 2016

NARROW

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma

Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL)

Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era

Impact of NPM1 / FLT3 -ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Transplant Associated Thrombotic Microangiopathy (TA-TMA) Commonly Occurs after Steroid-Refractory or Dependent Gastrointestinal (GI) Graft Versus Host Disease (GVHD) and Contributes to Post-Transplant Morbidity

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib

An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations

The Novel BET Inhibitor PLX51107 Has In Vitro and In Vivo Activity Against Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib

Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only